1.Efficacy of neoadjuvant radiochemotherapy in treatment of locally advanced low rectal cancer.
Bao-Ming YU ; Min ZHANG ; Wei-Qin WU ; Li-Wen CHEN ; Jun FU ; Chun-Song FEI ; Ying SHEN
Chinese Journal of Surgery 2007;45(7):445-448
OBJECTIVETo explore efficacy of neoadjuvant radiochemotherapy in locally advanced low rectal cancer.
METHODSFrom May 2001 to August 2005, 105 patients with locally advanced low rectal cancer (T3, T4) were treated by preoperative radiotherapy to pelvis, 2.0 Gy daily up to 40-46 Gy in 4-5 weeks concomitantly with oral capecitabine at 1250 mg x m(-2) x d(-1) for 10 weeks up to surgery. In all patients surgery was carried out under the rule of total mesorectal excision technique.
RESULTSAll patients finished the course of neoadjuvant radiochemotherapy. Among them, 36 patients experienced adverse effects. Thirteen patients resulted in complete tumor response and spared the operation. Ninety-two patients were operated on with radical resection, among them 71 patients with low anterior resection, 17 with Parks' colo-anal anastomosis and 4 with abdomino-perineal resection, so sphincter preservation was achieved in 96.2%. In postoperative pathological studies, 11 cases showed complete tumor regression. According to the TNM staging system, 24 cases were ranged T0N0, and 23 cases T2N0, 43 cases T3N0, 2 cases T4N0, 5 cases T2N1, 8 cases T3N1; and according to Dworak's tumor regression grading, 5 cases were ranked TGR0, and 18 cases TGR1, 11 cases TGR2, 47 cases TGR3, 24 cases TGR4. Pathologic downstaging was achieved in 78.1%, including complete response (TGR4) and intermediate response (TGR2 + 3). No operative death occurred. Anastomotic leakage was found in 5 cases, including 3 rectovaginal fistula. All patients have been followed up for 16-67 months, and lung metastasis occurred in 4 cases, liver metastasis in 2 patients and local recurrence in 4 patients. Three patients died of distant metastasis. The 3-year disease-free survival was 82.8% and overall survival was 96.5%.
CONCLUSIONSNeoadjuvant radiochemotherapy brings tumor down-staging and increases resectability and sphincter preservation, decreases recurrence and improves survival in locally advanced low rectal cancer.
Chemotherapy, Adjuvant ; adverse effects ; methods ; Disease-Free Survival ; Follow-Up Studies ; Humans ; Neoadjuvant Therapy ; adverse effects ; methods ; Preoperative Care ; methods ; Radiotherapy, Adjuvant ; adverse effects ; methods ; Rectal Neoplasms ; mortality ; surgery ; therapy ; Survival Rate ; Treatment Outcome
2.Evaluation of treatment response and tissue necrosis as prognostic indicators following neoadjuvant chemoradiotherapy in rectal cancer patients.
Ji Han JUNG ; Ho Jung AN ; Hyung Jin KIM ; Jonghoon LEE ; Kang Moon LEE ; Sung Hwan KIM ; Hyeon Min CHO ; Byoung Yong SHIM
The Korean Journal of Internal Medicine 2016;31(1):134-144
BACKGROUND/AIMS: The objective of this study was to assess the prognostic roles of treatment response and tissue necrosis after chemoradiotherapy (CRT) in locally advanced rectal cancer. METHODS: A total of 243 patients with locally advanced rectal cancer who underwent neoadjuvant CRT were included. Three treatment response groups were classified by their pathological stage results: complete treatment response (CTR), intermediate treatment response (ITR), and poor treatment response (PTR). Three tissue necrosis groups were classified based on tissue pathological results: complete necrosis response (CNR), intermediate necrosis response (INR), and poor necrosis response (PNR). RESULTS: Overall survival (OS) and recurrence-free survival (RFS) rate at three years were 74.5% and 61.3%, respectively. The 3-year OS rates of the CTR, ITR, and PTR groups were 83.7%, 75.9%, and 69.7%, respectively (p < 0.001); the 3-year RFS rates were 76.7%, 69.0%, and 52.1%, respectively (p < 0.001). The 3-year OS rates of the CNR, INR, and PNR groups were 83.7%, 80.6%, and 61.8%, respectively (p < 0.001); the 3-year RFS rates were 76.7%, 68.9%, and 44.3%, respectively (p < 0.001). When compared to CTR/CNR, PTR/PNR was strongly related to an increased risk of recurrence (hazard ratio [HR], 5.53; 95% confidence interval [CI], 2.01 to 15.23 vs. HR, 6.37; 95% CI, 2.29 to 17.74, respectively) in univariate Cox regression. Both PTR and PNR were strongly associated with shorter RFS and OS when compared with CTR and CNR in the multivariate Cox regression. CONCLUSIONS: Tissue necrosis is an equally important prognostic marker as treatment response for oncologic outcomes in locally advanced rectal cancer.
Aged
;
Biopsy
;
*Chemoradiotherapy, Adjuvant/adverse effects/mortality
;
Chi-Square Distribution
;
Disease Progression
;
Disease-Free Survival
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
*Laparoscopy/adverse effects/mortality
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Necrosis
;
*Neoadjuvant Therapy/adverse effects/mortality
;
Neoplasm Recurrence, Local
;
Neoplasm Staging
;
Proportional Hazards Models
;
Rectal Neoplasms/mortality/pathology/*therapy
;
Remission Induction
;
Retrospective Studies
;
Risk Factors
;
Time Factors
;
Treatment Outcome
3.Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.
Giuseppa SCANDURRA ; Giuseppe SCIBILIA ; Giuseppe Luigi BANNA ; Gabriella D'AGATE ; Helga LIPARI ; Stefania GIERI ; Paolo SCOLLO
Journal of Gynecologic Oncology 2015;26(2):118-124
OBJECTIVE: To evaluate the efficacy and tolerability of a neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy in patients with locally advanced cervical carcinoma. METHODS: Patients with histologically confirmed locally advanced cervical carcinoma, aged > or =18 years, were treated with intravenous ifosfamide 5,000 mg/m2 and mesna 5,000 mg/m2, on day 1; intravenous paclitaxel 175 mg/m2 and cisplatin 75 mg/m2, on day 2; every 3 weeks for three cycles. Following chemotherapy, operable patients underwent radical hysterectomy and pelvic lymphadenectomy, and, if necessary, adjuvant radiotherapy. RESULTS: One hundred fifty-two patients with median age 53 years (range, 24 to 79 years), FIGO stage IIB in 126 (89%), were treated with chemotherapy for median 3 cycles (range, 1 to 3). Treatment was delayed or withdrawn in 23 patients (15%). One hundred thirty-nine patients (91%) underwent surgery. Postchemotherapy pathological complete response rate was 18% (25 patients). Postoperative radiotherapy was administered in 100 patients (72%). The 5-year overall survival and progression-free survival were 87.3% (95% confidence interval [CI], 84.5 to 90.3) and 76.4% (95% CI, 73.5 to 79.5), respectively. CONCLUSION: Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy was feasible and effective in the treatment of locally advanced cervical carcinoma patients with older age and more advanced disease stage than reported in previous studies. Hematological and renal toxicity could be carefully prevented.
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Carcinoma, Squamous Cell/*drug therapy/mortality/pathology
;
Cisplatin/*administration & dosage/adverse effects
;
Disease Progression
;
Feasibility Studies
;
Female
;
Humans
;
Ifosfamide/*administration & dosage/adverse effects
;
Middle Aged
;
Neoadjuvant Therapy
;
Paclitaxel/*administration & dosage/adverse effects
;
Retrospective Studies
;
Treatment Outcome
;
Uterine Cervical Neoplasms/*drug therapy/mortality/pathology
;
Young Adult
4.Pulmonary Toxicity after a Quick Course of Combinatorial Vincristine, Bleomycin, and Cisplatin Neoadjuvant Chemotherapy in Cervical Cancer.
Kyung Do KI ; Jong Min LEE ; Seon Kyung LEE ; Seo Yun TONG ; Chu Yeop HUH ; Jung Kyu RYU ; Kyo Young KIM
Journal of Korean Medical Science 2010;25(2):240-244
Pulmonary toxicity is one of the most serious adverse effects associated with a quick course of vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy (NAC-VBP). The aim of this study was to evaluate pulmonary toxicity related to a quick course NAC-VBP. A total of consecutive 61 patients, who underwent at most 3 cycles of NAC-VBP every 10 days in the International Federation of Gynecology and Obstetrics (FIGO) stage IB-IIB cervical cancer from 1995 to 2007, were retrospectively analyzed. Of the 61 study subjects, 7 (11.5%) were identified to have pulmonary toxicity and 2 (3.3%) died of pulmonary fibrosis progression despite aggressive treatment and the use of a multidisciplinary approach. No factor predisposing pulmonary toxicity was identified. Initial symptoms were non-specific, but bronchiolitis obliterans organizing pneumonia and interstitial pneumonitis were characteristic findings by high-resolution computed tomography of the chest. The benefit of steroid therapy was uncertain and was associated with steroid-induced diabetes mellitus requiring insulin therapy in two patients. Fatal pulmonary toxicity is a major concern of a quick course NAC-VBP. In conclusion, these patients require special monitoring for bleomycin-induced pulmonary toxicity.
Aged
;
Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects/therapeutic use
;
Bleomycin/administration & dosage/*adverse effects/therapeutic use
;
Cisplatin/administration & dosage/*adverse effects/therapeutic use
;
Female
;
Humans
;
Lung Diseases/*chemically induced/pathology
;
Middle Aged
;
*Neoadjuvant Therapy
;
Pulmonary Fibrosis/chemically induced/mortality/pathology
;
Retrospective Studies
;
Tomography, X-Ray Computed
;
Uterine Cervical Neoplasms/complications/*drug therapy
;
Vincristine/administration & dosage/*adverse effects/therapeutic use
5.Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
Myeong Jun SONG ; Si Hyun BAE ; June Sung LEE ; Sung Won LEE ; Do Seon SONG ; Chan Ran YOU ; Jong Young CHOI ; Seung Kew YOON
The Korean Journal of Internal Medicine 2016;31(2):242-252
BACKGROUND/AIMS: We compared the recurrence of hepatocellular carcinoma (HCC) and the survival of patients who received radiofrequency ablation (RFA) after transarterial chemoembolization (TACE) with patients treated with TACE or RFA alone. METHODS: This study included 201 patients with HCC, who were consecutively enrolled at Seoul St. Mary's Hospital between December 2004 and February 2010. Inclusion criteria were a single HCC < or = 5.0 cm or up to three HCCs < or = 3.0 cm. We used a propensity score model to compare HCC patients (n = 87) who received RFA after TACE (TACE + RFA) with those who received TACE (n = 71) or RFA alone (n = 43). RESULTS: The median follow-up period was 33.3 months (range, 6.8 to 80.9). The TACE + RFA group showed significantly lower local recurrence than the RFA or TACE groups (hazard ratio [HR], 0.309; 95% confidence interval [CI], 0.130 to 0.736; p = 0.008; and HR, 0.352; 95% CI, 0.158 to 0.787; p = 0.011, respectively). The overall survival was significantly better in the TACE + RFA group compared to the RFA group (HR, 0.422; 95% CI, 0.185 to 0.964; p = 0.041). However, the survival benefit was not different between the TACE + RFA and TACE groups (p = 0.124). Subgroup analysis showed that among patients with a tumor size < 3 cm, the TACE + RFA group had significantly better long-term survival than those in the TACE or RFA groups (p = 0.017, p = 0.004, respectively). CONCLUSIONS: TACE + RFA combination treatment showed favorable local recurrence and better overall survival rates in early-stage HCC patients. Patients with tumors < 3 cm are likely to benefit more from TACE + RFA combination treatment. Additional studies are needed for the selection of suitable HCC patients for TACE + RFA treatment.
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Hepatocellular/mortality/pathology/*therapy
;
*Catheter Ablation/adverse effects/mortality
;
*Chemoembolization, Therapeutic/adverse effects/mortality
;
Chemotherapy, Adjuvant
;
Disease-Free Survival
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Liver Neoplasms/mortality/pathology/*therapy
;
Male
;
Middle Aged
;
*Neoadjuvant Therapy/adverse effects/mortality
;
Neoplasm Recurrence, Local
;
Neoplasm Staging
;
Patient Selection
;
Proportional Hazards Models
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Time Factors
;
Treatment Outcome
;
Tumor Burden
;
Young Adult
6.The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.
Cheolsu KIM ; Ho Sup LEE ; Chang Ki MIN ; Je Jung LEE ; Kihyun KIM ; Dok Hyun YOON ; Hyeon Seok EOM ; Hyewon LEE ; Won Sik LEE ; Ho Jin SHIN ; Ji Hyun LEE ; Yong PARK ; Jae Cheol JO ; Young Rok DO ; Yeung Chul MUN
The Korean Journal of Internal Medicine 2015;30(5):675-683
BACKGROUND/AIMS: The purpose of this study was to determine the correlations between inflammatory factors-including absolute lymphocyte count, lactate dehydrogenase, beta2-microglobulin, albumin, C-reactive protein, and ferritin-and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). METHODS: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. RESULTS: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 x 109/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively). CONCLUSIONS: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.
Adult
;
Aged
;
Antineoplastic Agents/adverse effects/*therapeutic use
;
Biomarkers, Tumor/*blood
;
Chemotherapy, Adjuvant
;
Disease-Free Survival
;
Female
;
Hospitals, University
;
Humans
;
Induction Chemotherapy
;
Inflammation Mediators/*blood
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Multiple Myeloma/blood/diagnosis/*drug therapy/immunology/mortality
;
Multivariate Analysis
;
Neoadjuvant Therapy
;
Odds Ratio
;
Proportional Hazards Models
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Stem Cell Transplantation
;
Thalidomide/adverse effects/*therapeutic use
;
Time Factors
;
Transplantation, Autologous
;
Treatment Outcome